Good morning. My name is Emma and I will be the conference operator today. At this time, I would like to welcome everyone to the Butterfly Network Q3 earnings call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. Thank you. Agnes Lee, you may begin your conference.

Good morning. And thank you for joining us today. Earlier this morning, Butterfly released financial results for the third quarter, which ended September 30th, 2021, and provided a business update. The release, and earnings presentation, which includes a reconciliation of management's use of non-GAAP financial measures compared to the most applicable GAAP measures are currently available on the investors section of the Company's website. Dr. Todd Fruchterman, Butterfly's President and Chief Executive Officer, and Stephanie Fielding, Butterfly's Chief Financial Officer, will host this morning's call. During today's call, we will be making certain forward-looking statements. These statements may include statements regarding, among other things, expectations with respect to financial results, future performance, the development of products and services, potential regulatory approvals, anticipated financial impacts, and other effects of the business combination on our business. The size and potential growth of current or future markets for our products and services, and the potential impact of the COVID-19 pandemic on our business. These forward-looking statements are based on current information, assumptions, and expectations that are subject to change, and involve a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These and other risks are described in our filings made with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements. And the Company disclaims any obligation to update such statements. During this call, we will refer to non-GAAP financial measures, including adjusted gross margin, adjusted gross profit, and adjusted EBITDA. These financial measures are not prepared in accordance with U.S. Generally Accepted Accounting Principles or GAAP. These non-GAAP financial measures are not intended to be considered in isolation or as substitutes for the results prepared in accordance with GAAP. The definitions and reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures, and a discussion of why we present these non-GAAP financial measures are included in today's press release and at the end of the slide presentation. As a reminder, this call is being webcast live and recorded, and we will be referencing a slide presentation in conjunction with our remarks. Because there is a short delay between live telephone audio and the presentation being shown on the webcast, for the best experience, please use either the webcast for both audio and video content, or if you've dialed in by telephone, download the slides from our website in advance. To access the webcast, please visit the Events section in the Investors section of our website and a replay of the event will be available following the call. I would now like to turn the call over to Dr. Fruchterman.

Thank you, Agnes, and good morning, everyone. We appreciate you taking the time to join us and learn about our progress this quarter. There is much for our team to be proud of as we build our foundational strength and make advancements toward realizing our vision of democratizing medical imaging and transforming care by enabling more informed clinical decision-making. And while we are improving every day, based on our most recent experiences and the current healthcare environment, we must reset expectations for revenue for the balance of the year. While our revenues for Q3 grew 44% year-over-year, we are falling short of what's necessary to achieve the annual guidance provided by prior management one year ago and reaffirmed by me in May of this year with the information I had, having just joined the Company. For 2021, we now expect full-year revenue growth in the range of 30% to 34%. This represents good progress in our current commercial activities in mounting user enthusiasm about Butterfly, but is offset by healthcare logistical challenges, and doctor, nurse, and medical technician fatigue stemming from COVID conditions and its broad consequences. To understand our user base, it is important to recognize that there are multiple layers of Butterfly users. Many individual practitioners and early technology adopters are excited about our portability, affordability, and breadth of utility. We appreciate their early adoption, advocacy, and feedback. Many of them have been engaged in life-saving, practice-altering work, and hold a deep understanding of how Butterfly can improve decision-making to both accelerate and enhance care delivery. A second group of users across multiple specialties is increasingly adopting Butterfly, as we properly segment, educate, and integrate the power of Butterfly into their respective areas of practice. Here we are focusing on specific capabilities of this system and helping users to rapidly incorporate it into their practices and workflows. Over the coming quarters, we will continue to roll out programs targeted at specific specialties and procedural use cases, and are aligning commercial energies around doing so. Finally, because of the unique aspects of Butterfly, we are well-positioned to increasingly engage a third group of users, large integrated health systems. Our value proposition reaches wide for the enterprise user across many divisions, departments, and sites of care. As we alone can integrate new clinical data and insights conveniently, cost-effectively, and at enterprise scale. We expect our journey with hospitals and health systems to be collaborative as we work together to practically unlock valuable clinical information that will fundamentally change the course of diagnosis and treatment of patients in a variety of care settings. Such enterprise engagements require close integration to optimize enterprise workflows and systems, and ensure proper compliance, security, building integrity, and continuity. Introducing Butterfly to the enterprise is less about sales cycles and more about partnerships, and we are pleased with our current momentum among this important user audience. Across all three layers of customers, in all geographies, we need to recognize that we are early in our journey and that commercialization, development, and clinical advancement will be iterative. One clear thread that permeates all of our customer lanes is our commitment to consistently and persistently drive ease of use and simplicity. Delivering ease of use and simplicity in all we do is a north star for our journey and will be a clear value differentiator in the market, and there's a personal commitment from our team and from me as we support doctors, nurses, and technicians to help them more effectively transform the way they practice medicine. It's important to note that there has been a significant management evolution since projections were first made that included an aggressive back half 2021 ramp. While we have rapidly reoriented strategy team, and the Company overall to adjust the need to shift from a direct-to-user led market approach to a more integrated commercial approach to health systems and specialties, our near-term performance has been negatively influenced by a confluence of factors. We believe that many of these factors are transitory and that our commitment to evolve and expand our commercialization approach, while constructively supporting behavior change in clinical practice, will be a long-term competitive advantage and one that Butterfly, with its innovative solution, is well-positioned to do. On a macro level, it is well understood that the healthcare community is suffering from exhaustion and severe human resource constraints resulting from the most recent COVID-19 Delta wave, as well as overall labor shortages. Butterfly was specifically developed to support these very medical professionals in their ability to diagnose and treat more effectively, more rapidly, and more affordably. Amid these unprecedented times, however, we have seen prospects and customers alike have to shift their attention to the pressing issues of the times rather than focusing on deploying new technology or adopting large-scale behavior change. We expect that these conditions will pass, but we do not expect them to disappear during Q4. To further respond to the needs and opportunities of the market, we have strengthened our talent in areas to enhance enterprise customer and prospect engagement and augment solution ease-of-use. These changes have resulted in high-value work streams that are currently active, and we believe will significantly accelerate growth in 2022 and beyond. The leading indicators of this progress are the quality of the leadership team we are building, improving customer satisfaction, which is evident in our Q3 sequential uptick in net promoter scores, and our in-process discussions with large institutions to kick-start enterprise-level implementations, all of which give me great optimism about future business acceleration. We believe Q3 and Q4 revenues are a lagging indicator that reflect the transitory challenges I just described. Butterfly is digital health in practice. Our disruptive system is uniquely positioned to deliver the value of better clinical information at the time it is needed. And our evolution to emphasize enterprise-level commercial strategies carries with it, our commitment to listen, learn, create, collaborate, and rapidly develop solutions that maximize not only the amazing utility of Butterfly, but enhance its ease of integration for those who will implement Butterfly at scale. Our goal is not simply to replace larger, more expensive technology with one that is more affordable. That alone is admirable and an obtainable goal, but falls short of our societal and commercial aspiration. The differentiated power of Butterfly is that it guides better clinical decision-making and subsequent care planning in a practical, cost-effective way. Butterfly has the technology and capability to fundamentally change the way medical information is gathered, decisions are made, and care is delivered. With Butterfly, clinicians can dramatically improve diagnosis accuracy and speed, inform the course of treatment, and provide an unmatched patient experience and better outcomes, regardless of care setting. An important component of bringing Butterfly public and obtaining more than $500 million of funding was the understanding that maximum impact would be created through connectivity and collaboration with frontline healthcare professionals and industry thought leaders. You see our commitment to that in the leadership team we have assembled and the board members who have joined us. In the coming quarters, you will see that confirmed by larger collaborations with institutions of scale who share our vision to dramatically improve the standard of care by deploying Butterfly as an advanced assessment tool throughout our institutions and systems. To further support our go-to-market approach, in only a matter of months, we have reoriented our technology group under the leadership of CFO Andre Andrei Stoica, to include industry-leading best practices for enterprise and workflow software development to bring agility and speed to our enablement of larger scale enterprise collaborations. This is not only reflective of the iterative journey of co-development we are undertaking but is demonstrative of our perpetual commitment to emphasize ease of use and take more of the user burden onto the device and system, whether it be at the platform level, the solution level, or with our investment in AI. Furthermore, we understand that a component of enabling ease of use requires removing implementation barriers to facilitate behavior and practice change. At the beginning of the journey, enhancing education is critical. This is why we continue to build and optimize our team around these critical priorities. We have augmented our clinical leadership under the direction of Dr. John Martin to better participate in and drive expansive clinical conversations with prospective partners as a means to advance the evolution and incorporation of ultrasound information into clinical workflows. We have also revamped our sales organization under our Chief Commercial Officer, Stacey Pugh, to give us the human capital necessary to more deeply engage with our clients. We have complemented our internal investment in AI with an exclusive agreement with Caption Health, which I will discuss in more detail later in the call. I recognize that it is frustrating to the investment community and to our management team that you cannot see the full evidence of our progress in the revenue stream in the back half of 2021. But we believe we are making significant progress and are better positioned to capture the full potential of Butterfly moving forward. Despite our revenue shortfall, our adjusted gross margin, and adjusted EBITDA are projected to exceed the original plan, and we continue to invest aggressively in products, people, and commercial expansion. Our underlying momentum is building and we expect to see accelerating revenue growth in 2022. We will communicate our complete 2022 forecast to the investment community concurrent with our Q4 earnings release and investor call. However, I will share with you today that we are confident that our rate of revenue growth for 2022 will exceed our projected full year 2021 growth rate. We have made significant and measurable headway in 2021 and our team is sprinting forward. As a true growth Company, I want to reiterate my personal passion and conviction that we are here to invest higher, build, partner, collaborate, and co-create across all aspects of Butterfly. We will enable superior image and data capture everywhere and anywhere, from assessment in traditional healthcare channels, alternative sites of care, to the home, across specialties that have never had access to timely imaging information before, and within geographies that have never had high-quality medical imaging. We know that every version of success for Butterfly starts with building a highly talented, capable team to support our vision and growth. I'd like to share a few leadership updates from this quarter. To support oversight on our growth and innovation strategy, we expanded our board with the appointment of Dr. Erica Schwartz. Dr. Schwartz brings a breadth of healthcare management and public health experience to the Board of Directors. Most recently serving as Deputy Surgeon General for the U.S. Department of Health and Human Services, where she led the country's public health deployment and response to the COVID-19 pandemic. She also spent 24 years in the uniform service with the U.S. Coast Guard, serving as Chief Medical Officer, and then other leadership roles. Dr. Schwartz will serve on our newly formed technology committee with Dr. Rothberg and Dr. Edelman, providing oversight of the role of technology in executing our strategy and supporting our business and operating requirements. As we continue to scale and expand the business, we have been adding executive leadership in areas that would support our strategy and initiatives to accomplish this. In the third quarter, we added Troy Quander as our Senior Vice President, Regulatory and Quality to lead this critical capability. He brings over 25 years of FDA and industry experience with a focus on regulatory affairs, compliance, quality, and post-market surveillance teams. Troy previously held roles at Olympus, Roche, Becton Dickinson, OraSure Technologies, Johnson and Johnson, and BioMérieux. With the addition of Troy to our existing regulatory and quality team, Butterfly further strengthened our ability to bring additional innovative solutions to market in a compliant and timely fashion. I'm very happy with the rapid evolution of the leadership team and with the addition of Troy, we have become even stronger to take us through the next part of our journey. We also find confidence and are encouraged by the growing evidence in scientific publications that demonstrate Butterfly's use across different settings and phases of care. Recently, the New England Journal of Medicine published an article that talked about the growing use of point-of-care ultrasound (POCUS) and factors that have led to broader adoption being driven by the advent of smaller, more affordable ultrasound machines combined with evidence that physicians without a radiology background can use them effectively in practice. Beyond publications, there are more and more stories spanning a variety of procedural areas being told by physicians who are using Butterfly in their practices in institutions. One that I would like to highlight was presented at Pacira Biosciences' recent Investor Day. Pacira is a specialty pharmaceutical Company that creates therapeutics to manage pain. An anesthesiologist from a leading academic medical center walked investors through a timeline about the use of regional anesthesia during surgery. He then showed a picture of Butterfly as a disruptive technology that has enabled the broader adoption of regional anesthesia to improve patient care and post-operative recovery. Even with extensive training, it is challenging to administer regional anesthesia without complications. Butterfly changes that. With our solution and Needle Viz technology, the anesthesiologist can see the targeted area and safely and effectively administer the anesthetic. This is what Butterfly makes possible. There is more to come as we meet the needs of our customers and innovate so that Butterfly is not just accessible but present in the pocket of all physicians and healthcare providers everywhere and anywhere. Another important enabler of behavior change is ease of use. In August, we announced an exclusive partnership with Caption Health, the creator of Caption AI, the first and only FDA-cleared AI guidance ultrasound software. And the recent recipient, not only of a technology add-on payment or NTAP from CMS but also of Time Magazine's best invention of 2021 recognition. With an AI-powered Butterfly and Caption solution, we believe we can meaningfully enhance cardiac assessment. Specifically, our integrated solution will take on more of the burden of capturing and interpreting the ultrasound while providing practitioners with quick and relevant information about a patient's cardiac state. Not only is there significant opportunity to better manage identified cardiac conditions, but there's also considerable undetected disease across our communities. As a recent study from Circulation Heart Failure showed, 46% of heart failure patients diagnosed in the acute care settings had potential heart failure symptoms during primary care clinic visits in the previous 6 months. We believe that advanced diagnostic solutions, like the one we'll bring to market with Caption, may be able to help identify undiagnosed heart failure earlier and bring people to therapy sooner before they get sicker, resulting in fewer unnecessary acute care visits and decreased medical costs. Butterfly and Caption Health are expected to introduce the combined platform on Butterfly iQ+ in the U.S. later this winter. Another way to expand access to information is through unlocking new markets. As we evolve as a Company, global expansion will become a greater focus as the demand for Butterfly grows everywhere. We are excited to share continued momentum in the growth of our distributor relationships, a key mechanism to expand our reach. You will recall that last quarter we shared our entry into the Hong Kong region with a partnership with Chindex Medical. True to our mission to democratize care around the world, I'm pleased that through partnerships we entered into this quarter, we will make Butterfly available in Chile, Pakistan, and through a more recent strategic partnership with Abdul Latif Jameel Health, we will bring Butterfly to the Middle East, North Africa, Turkey, and India. With these activities, we are helping to address global health equity needs by introducing Butterfly to markets that need better, more advanced technology and information to deliver a higher standard of clinical care. And this is not just about creating access. One focus area for our partner in Pakistan will be on improving health outcomes for expectant mothers, leveraging the affordability, portability, and capabilities that are unique to the Butterfly solution, such as the new OB tools, including the gestational age calculator that we launched last quarter. They will be partnering with provincial governments to aid healthcare workers to take Butterfly devices into the homes of pregnant mothers and provide access to care that otherwise is just not available. Another important driver of our growth is organic innovation. This quarter, we released a new product for the veterinary market. We launched Butterfly iQ+ Vet, our second-generation veterinary ultrasound device, which is designed to bring more valuable information and capabilities to veterinarians in a variety of clinical settings. The iQ+ Vet has many new features, comes with color Doppler sensitivity, and Needle Viz tool. Notably, it was designed with a 15% smaller probe face and a 10% shorter probe for easier overall use and maneuvering. With the introduction of iQ+ Vet, we have also expanded our market reach. The product is now available for purchase in 19 new international markets. We continue to grow with large-scale partnerships and distributor relationships in the U.S. and now the UK. We are very excited to bring value to the veterinary market in parallel with our work in human healthcare. Additionally, we announced a large-scale partnership with Rarebreed to bring Butterfly to all of their veterinary hospitals. This adoption reflects an important change in the perception and deployment of Butterfly that is different from traditional ultrasound use in veterinary medicine. Rarebreed had several experiences with Butterfly that catalyzed their decision to adopt across their hospitals. There is one instance that I would like to share with you. A veterinarian at a Rarebreed hospital worked with a dog reported to have lumps by the owner. The veterinarian performed a physical exam and used Butterfly to perform a quick ultrasound of both lesions where the vet noticed marked sonographic differences between them. This led the vet to perform a quick fine needle aspirate, which led to a diagnosis of a tumor. The vet then used Butterfly to ultrasound the liver and spleen to look for metastatic disease. All of this occurred during one appointment. Rather than waiting to obtain insight by referring out to a specialist, the veterinarian was able to acquire valuable information to guide an accurate diagnosis and provide information immediately to the pet owner, reducing the stress associated with waiting for a diagnosis and allowing the owner to focus on the wellness of the pet. I hope this story helps to illustrate yet another flavor of what Butterfly makes possible. Before I turn it over to Stephanie for a more detailed financial discussion, I want to reiterate a number of points that I think are crucial to understanding our direction. Butterfly's great potential is to re-imagine healthcare by enabling more informed care decisions. The differentiated power of Butterfly is that it unlocks ultrasound information in a practical, cost-effective way. Through the confluence of a transformational device that enables information acquisition and innovative software that makes the information usable, we are creating an entirely new clinical experience. We know that changing behavior requires hard work, and we are now well-positioned to drive this positive change. We will relentlessly pursue simplicity and ease of use to enable Butterfly to be used in the broadest number of locations by the broadest number of users across a range of clinically meaningful and impactful applications and settings. We don't just want to make clinicians better; we want Butterfly to make practitioners better clinicians. We are already in the process of changing clinical behavior, and we are continuing to see proof points that acknowledge the use of ultrasound to establish a clinical diagnosis or to guide a procedure. Even with the challenges of the current environment, we continue to build momentum and are still seeing strong demand for Butterfly. And finally, in my eight months at the Company, my commitment and excitement have only grown stronger. I will now turn the call over to Stephanie for a review of our financial results.

Thank you, Todd, and good morning, everyone. Third quarter revenues grew 44% year-over-year to $14.6 million, and adjusted gross margin came in at 49.3%. While these numbers are healthy, they fell short in the ramp that's necessary to meet our original revenue projections. Product revenue for the quarter was $10.8 million, an increase of 25.8% from $8.6 million in the same period in 2020. Units fulfilled, the main driver of product revenue, were $5,556 in the quarter compared with $3,947 in Q3 2020, an increase of 41%. Growth was driven by increasing traction from our direct sales force performance in our veterinary business and new distributor relationships in Chile and Pakistan, partially offset by direct-to-user sales that abated. On a related note, during the quarter, we increased the price of Butterfly iQ+ to $2,399. We believe we are seeing the end of the individual early adopter curve and we believe direct-to-user sales slowed this quarter due to a combination of the challenging environment for medical professional time and attention due to COVID surges, labor shortages, and a short-term reaction to our pricing actions in August. It is also a reflection of the patterns with the direct-to-user audience that we anticipated, which validates our expanded focus on health institutions and a more tailored outreach to individual users. We have no plans to offer any hardware price promotions during the holiday season, as we did in Q4, 2020 when we introduced the Butterfly iQ+. We are not modeling any significant acceleration in our direct-to-user trends other than normal buying patterns in Q4. We continue to enhance our customer and prospect engagement through our website, expanding commercial activities, targeting users by specialty, and supporting their education. Subscription revenue was $3.8 million in the third quarter, growing approximately 149% from $1.5 million in Q3 2020. Our subscription mix, which we define as a percentage of total revenue recognized in our reporting period that is subscription-based, was 26% compared with 15% in the third quarter of 2020, an 11-percentage point increase. Turning now to adjusted gross profit and adjusted gross margin, reconciliation calculations to GAAP can be found in today's press release and at the end of the slide presentation. Adjusted gross profit was $7.2 million in Q3 2021, compared to adjusted gross profit of negative $2.7 million in Q3 2020. Excluded from the adjusted gross profit in Q3 2021 is a non-recurring $11.6 million loss on our purchase commitment with a third-party manufacturing vendor. Based on our current estimates, we are taking a reserve on inventory that we may not be able to use. There is no cash impact from this adjustment. This reserve does not preclude us from using the inventory in the future should circumstances change. We continue to believe that our access to semiconductor wafers in such an uncertain environment is an advantage enabling Butterfly to support future demand. Adjusted gross margin was 49.3% for the third quarter and 49.2% year-to-date, which compares to an adjusted gross margin of negative 26.3% in Q3 2020 and negative 10.8% for the first three quarters of 2020. Our healthy gross margin will provide leverage as we grow, and it's a significant improvement to our 2021 financial position. Operating expenses were $51.9 million for Q3 2021, an increase of $29.3 million, or 130%, compared to Q3 2020, due primarily to the build-out of our team in 2021, investments in innovation, and public Company expenses. The growth in operating expenditures reflects both the investments we are making to capitalize on the opportunities we see to transform care and the constrained spend environment in which the Company operated in the prior year. Loss from operations was $57 million, a decrease from negative $91.8 million in Q3 of 2020, primarily driven by higher operating expenses offset by the increase in gross margin. Net loss was $13.6 million as compared to a net loss of $92.2 million during the third quarter of 2020. Our net loss was positively impacted by a $43 million non-operating gain due to the change in fair value of our warrant liabilities, which did not exist in 2020. Adjusted EBITDA was a loss of $33.5 million, compared with a loss of $22.6 million in the same period in 2020. Adjusted EBITDA reconciliation calculations to GAAP net loss can be found in today's press release. Moving to our capital resources, we have a strong cash position that allows us to continue investing in our journey. As of September 30th, 2021, cash and cash equivalents and marketable securities were $468.4 million. Of note, inventory in the third quarter was $23.8 million, a $23.1 million decrease from the $46.9 million reported in the second quarter of 2021. This decrease was due to a balance sheet reclassification from our purchase commitment liability. As we have continued upgrading our product to increase reliability and position ourselves for future transformational technology, we have determined that older raw material is likely obsolete. Consequently, we re-classed $35 million of that older raw material from reserve against the inventory to a reduction in inventory. This decrease in inventory was partially offset by additional purchases of raw materials subject to our minimum purchase commitments. In light of the theme Todd discussed earlier regarding the backdrop of COVID on healthcare, which has delayed system implementations in institutions, a longer sales and development cycle related to health systems adoption, and the trends we are seeing in direct-to-user purchases, we are adjusting our 2021 guidance to reflect our views on the current pace of market adoption. For the full year 2021, total revenue is projected to be approximately $60 million to $62 million, or 30% to 34% growth year-over-year. Through the third quarter, we have seen consistent performance in adjusted gross margin and slower ramps in our expenses. As a result, we have also updated these financial trends in our guidance for full-year adjusted gross margin and adjusted EBITDA. Gross margin is expected to be between 20% to 30%, and the net loss is expected to be between $65 million to $75 million, assuming no change in the fair value of our warrants. Adjusted gross margin is expected to be between 48% to 50% and adjusted EBITDA is expected to be negative $125 million to $135 million. And with that, I will now turn it back over to Todd for summary comments.

Thank you, Stephanie. And thank you all for participating in Butterfly's third quarter 2021 earnings call. I would also like to thank the Butterfly team for their dedication to our mission and the excellent progress we have made in Q3. We are well on our journey of changing clinical behavior at scale from our innovation and momentum to empower individual practitioners and care teams, to our ongoing expansion across the U.S., globally, and even beyond. Thank you for your time today, and I look forward to providing ongoing updates as we deliver upon our mission to democratize medical imaging and to position Butterfly as an indispensable tool in healthcare—one that is truly unique in its capability to enable more accessible, affordable healthcare to patients around the world, anywhere and everywhere. We will now turn the call over for questions.

Your first question comes from the line of Matt Taylor from UBS. Your line is open.

Thanks. Good morning. Thanks for taking the question. I was wondering if you could maybe just give us a sense for what you think the overall focus market is growing. And maybe just talk about your share within that. Any updated views that you have on the market backdrop?

Good morning and thanks for the question. I think we continue to believe that the total addressable market (TAM) for the opportunity is incredibly large, given the versatility of the solution that we have. I don't think that our perspective on the opportunity has changed with any circumstances that have occurred this quarter. We continue to see signs of the market responding, and we cited the New England Journal of Medicine. Those are the types of indications that continue to give us confidence and excitement about what we're seeing in the reactions in the market. But there's nothing short-term that's adjusted our perspective on the opportunity, and we continue to be excited about the size of that TAM.

And I think, Matt, the other thing is while we continue to be very excited about the opportunity, Butterfly is not traditional point-of-care ultrasound (POCUS). And really that's what we are evolving and working on right now. So, as we look at the term that's considered in the market around POCUS, it's a lot around current thinking and Butterfly, with all of its capabilities, allows people to leverage those attributes and incorporate them into different workflows. So, the capabilities of needle visualization, bladder scanning, and you can bring it in as an assessment tool and into a workflow tool. And also use it as an advanced assessment tool leveraging ultrasound information into clinical workflows that are informing clinical decision-making. We see the opportunity as the focus—current focus plus, because of what Butterfly can do with its affordability, portability, and capabilities.

Your next question comes from the line of Josh Jennings from Cowen. Your line is open.

Hi, good morning. Thanks for taking the questions.

Good morning, Josh.

Todd and Stephanie. Good morning. I wanted to understand that the Q3 and Q4 results are lagging indicators, and I was just hoping to learn a little bit more about what's driving the optimism you talked about regarding momentum in the business. I'm assuming it's in the enterprise channel, maybe if there are any leading indicators for the outlook, and how they've evolved since the Q2 call. In the risk of just not being allowed to ask a follow-up and getting disconnected. Just on the 2022 outlook, could you share from a high level, outside of the stronger adoption in the U.S. enterprise channel, any other growth drivers that you would call out that you expect to drive acceleration in revenue growth in 2022 from 2021? And then any other pipeline updates or actions that we should be thinking about as we move through the next 12 months? Thanks for taking all the questions.

Alright. Thanks, Josh. I'm going to try to unpack that. Let me start, and then if I don't capture it all, you can follow up. First let me start by saying, I think this is a lot less about things not happening and more about things not happening yet. We're seeing a lot of positive conversations and signals. This is really around behavior change in care evolution, so our optimism is driven a lot by the conversations that we're having at the larger institutional level about incorporating Butterfly, not as POCUS, but as an integral tool weighted differently about workflows in different aspects and functions within the hospital. So that's driving a lot of our optimism. As we think about how we are looking at the market, when Butterfly came about, it was a real technological advance. We think that our single-probe whole-body ultrasound and Ultrasound-on-Chip provides a lot of advantages to the evolution of ultrasound information across the continuum of care. When Butterfly came to market, it was marketed as a device that was here, and I think that was a great way to introduce it into the market. As we go into 2022, we're taking a much more targeted approach and a much more connected approach to the users from both an institutional perspective and a specialty perspective. So how you can incorporate Butterfly more seamlessly into workflow and into practice. A lot like new technologies, when you start adopting something that's new, that you haven't had, it's about getting people comfortable with it and getting them to use it for specific cases and then expanding it. We made it available when Butterfly entered the market. Now, what we're doing is focusing very much on how people can get value by using it. And so, with the information you can acquire from the device itself and then how we can make that information incorporated into workflows. We're taking a more specialty approach with a much more focused utilization to help people incorporate it into their practices. We're taking a much more partnered approach with enterprises and institutions, that's really about co-development for true value realization across the entire institutional approach. When you think about traditional POCUS, medicine can't be practiced differently anymore in one building versus another. To think that you have ultrasound machines in hospitals, and you're delivering a certain level of care and getting information to make decisions, you don't have that elsewhere when so much caregiving outside the hospital is just going to be a challenge moving forward. We see as more care and more decisions are being made outside of the hospital, even more excitement generating about Butterfly, and then that continuum of new information being utilized to help drive consistency of workflow in decision-making across the continuum as being a real advantage for Butterfly. We think one of the things that's really exciting about that is our positive indicator is that our customers are seeing that too.

Thank you for that. Could you provide some insight on how we should view the expansion of international and veterinary channels as we move into 2022? Will these channels be more significant contributors in 2022 compared to 2021?

Absolutely, Josh. I mean, we try to be super realistic about things. We're very early in our journey. We're early in our journey as a Company and we're early in our journey as a technology that's evolving care. So, we see in 2022 real good optimism and a lot of excitement in the enterprise and the institutions I just talked to you about. We see it across the continuum of care. We see it in geographical expansion, considering both developed and developing markets outside of the U.S. as a journey across that continuum. We see utilization of ultrasound outside of the human market. We're getting tremendous amounts of excitement for Butterfly in the veterinary market, and we are very excited about 2022. What's really cool is that people in the veterinary market are starting to think about Butterfly the same way we want people in the human market to think about it. How do you approach care delivery differently by incorporating Butterfly and ultrasound information into your decision-making early? That's been really exciting. So, we're really excited about multiple avenues to generating growth in 2022.

Great. And then one last layer on the pipeline and you have Caption coming onboard, anyway you can detail when that, I guess, the full launch of the integrated platform could occur if NTAP is kicking in here, or just did. And then any other software or next-generation platform updates, just in terms of timelines, we should think about that could catalyze new technology interactions that could catalyze stronger adoption utilization trends. Thanks again.

Hi, Josh. Thanks. As I said earlier on the call, we're on track for the launch with Caption in the winter this year. We're excited about introducing it into the market. We're really excited about bringing it into the market because I think it exemplifies what we've been talking about, which is taking the burden onto the device and away from the user. It's really less about doing procedures with ultrasound and more about information and decision-making. We think Caption really helps us demonstrate that and allows people to think about that information influencing care decisions earlier and differently than they may have in the past. We're excited about that. You'll see that in the winter coming out here. Regarding our development pipeline, we're really excited about the great progress that our technical teams have been making. Andres is in, the technical teams are realigned, and I think we're making a lot of progress on our software. We're getting very close to our customer needs and being very customer-centric. You'll see the normal cadence of us with software releases coming out in a timely fashion in the near future, and then hardware releases in that couple-year timeframe. As we look at the evolution of our technology, we're really excited about how our technical organization is performing and we're bringing it all together. The behavioral change with ease of use is taking that help in the device, taking more of the burden. We’re leaning into our clinical organization and generating data and our clinical education, helping users incorporate this technology and information into their clinical practices. That's really where our lean for 2022 is—to help accelerate our growth.

Thanks so much.

There are no further questions at this time. This concludes today's conference call; you may now disconnect.